
Adlarity has 7 Advantages over Donepezil Tablets
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets for Alzheimer’s.
A neuroradiologist at the Mayo Clinic in Jacksonville, FL warns that increased use of monoclonal antibody treatment for Alzheimer’s has also led to the discovery of amyloid-related imaging abnormalities — ARIA. Find out more.
The first drugs for Alzheimer’s disease emerged in the 1990s, but since then there has been a wave of clinical trial failures, major companies pulling resources from neuroscience R&D, and progress.
Dr. Robert Przybelski has prescribed lecanemab to real-life patients, and discusses his experience prescribing and administering the treatment.
Now, a third new Alzheimer’s drug expected to be approved by the Food and Drug Administration (FDA),. The field of new drugs is beginning to show progress in the fight to slow the disease.
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons.
First drug to modestly slow Alzheimer’s cognitive decline, based on 1,800 patients.
The FDA Advisory Committee’s endorsement of Leqembi paves way for traditional approval, ushers in a new era for Alzheimer’s
The FDA has approved the supplemental New Drug Application (sNDA) of REXULTI® (brexpiprazole) for the treatment of agitation associated with Alzheimer’s. It’s the first such treatment to be approved in the US. Learn more.
Eli Lilly Company’s TRAILBLAZER-ALZ 2 Phase 3 study shows that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Learn more.
So many people wait years for a dementia diagnosis—long after symptoms begin. Why? And what can we do about it now?
Got enough sunshine? Learn how sunshine seems to offer a bright, simple way to lower your risk of dementia.
Strength is not in our muscles. It is in our soul and spirit.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.